ArticleStroke2012
The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study.
Article in Stroke, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study To Determine The Safety Of Argatroban Injection In Combination With Tissue Plasmingen Activator (TPA) In Patients With Acute Ischemic Stroke
ARTSS-2: A Pilot, Phase 2b, Randomized, Multi-center Trial of Argatroban in Combination With Recombinant Tissue Plasminogen Activator for Acute Stroke
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- Guidelines for Intravenous Thrombolysis (Recombinant Tissue-type Plasminogen Activator), the Third Edition, March 2019: A Guideline from the Japan Stroke Society.Neurologia medico-chirurgica · 2019Guideline
- The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke.Stroke and vascular neurology · 2017Guideline
- Guideline
- Circadian Rhythm and Efficacy of Argatroban in Ischemic Stroke with Alteplase: A Post Hoc Analysis of the ARAIS Trial.CNS drugs · 2026Trial
- Argatroban plus alteplase in posterior versus anterior circulation stroke.Annals of clinical and translational neurology · 2025Trial
- Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.The New England journal of medicine · 2024Trial
- Baseline neurological deficit and argatroban plus alteplase in acute ischemic stroke: A post hoc analysis of ARAIS trial.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024Trial
- Argatroban Increased the Basal Vein Drainage and Improved Outcomes in Acute Paraventricular Ischemic Stroke Patients.Medical science monitor : international medical journal of experimental and clinical research · 2020Trial
- Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).Stroke · 2017Trial
- Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers.Current pharmaceutical design · 2013Trial
- Acute Ischaemic Stroke: Therapeutic Targets and Key Modulators of the Fibrinolytic System and Clot Formation.Translational stroke research · 2026Review
- Safety and effects of continuous argatroban administration in acute cerebral infarction: a retrospective analysis.Journal of pharmaceutical health care and sciences · 2026Article
- Thrombus Composition and the Evolving Role of Tenecteplase in Acute Ischemic Stroke.Journal of clinical medicine · 2025Article
- Adjunctive Antithrombotic Medications to Acute Reperfusion Therapy: Current Evidence and Future Directions.Stroke · 2025Review
- Association Between Argatroban and Outcomes of Branch Atheromatous Disease: A Propensity-Matched Analysis From MRI-Based Study.CNS neuroscience & therapeutics · 2025Article
- Article
- Early wide systolic pressure excursion is associated with clinical outcomes in acute branch atheromatous disease.Frontiers in neurology · 2025Article
- Efficacy of argatroban plus alteplase according to time from onset to thrombolysis in acute ischemic stroke: a prespecifiedFrontiers in neurology · 2025Article
- Argatroban in patients with acute ischemic stroke with early neurological deterioration: a cost-effectiveness analysis from the perspective of Chinese healthcare system.Frontiers in pharmacology · 2025Article
- Before, during, and after: An Argument for Safety and Improved Outcome of Thrombolysis in Acute Ischemic Stroke with Direct Oral Anticoagulant Treatment.Annals of neurology · 2024Review
Corrections and comments
- Commented on by
Authors and funding
21 authors at 1 institution in 1 country.
Funding
Abstract
background and purposeArgatroban is a direct thrombin inhibitor that safely augments recanalization achieved by tissue-type plasminogen activator (tPA) in animal stroke models. The Argatroban tPA Stroke Study was an open-label, pilot safety study of tPA plus Argatroban in patients with ischemic stroke due to proximal intracranial occlusion.
methodsDuring standard-dose intravenous tPA, a 100-μg/kg bolus of Argatroban and infusion for 48 hours was adjusted to a target partial thromboplastin time of 1.75× baseline. The primary outcome was incidence of significant intracerebral hemorrhage defined as either symptomatic intracerebral hemorrhage or Parenchymal Hematoma Type 2. Recanalization was measured at 2 and 24 hours by transcranial Doppler or CT angiography.
resultsSixty-five patients were enrolled (45% men, mean age 63±14 years, median National Institutes of Health Stroke Scale=13). The median (interquartile range) time tPA to Argatroban bolus was 51 (38-60) minutes. Target anticoagulation was reached at a median (interquartile range) of 3 (2-7) hours. Significant intracerebral hemorrhage occurred in 4 patients (6.2%; 95% CI, 1.7-15.0). Of these, 3 were symptomatic (4.6%; 95% CI, 0.9-12.9). Seven patients (10%) died in the first 7 days. Within the 2-hour monitoring period, transcranial Doppler recanalization (n=47) occurred in 29 (61%) patients: complete in 19 (40%) and partial in another 10 (21%).
conclusionsThe combination of Argatroban and intravenous tPA is potentially safe in patients with moderate neurological deficits due to proximal intracranial arterial occlusions and may produce more complete recanalization than tPA alone. Continued evaluation of this treatment combination is warranted. CLINICAL
trial registrationURL: www.clinicaltrials.gov. Unique identifier: NCT00268762.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.